drug Archives - Weed Reader

Culture, Marijuana Legalization, Marijuana News, Medical, Research, ScienceSeptember 20, 2017 by Adam Rhodes

MEDS Act Sponsored by Senator Hatch

Senator Hatch Introduces the MEDS Act.

The Marijuana Effectiveness Drug Study Act (MEDS Act) was just sponsored by Senator Orrin Hatch from Utah. If you have ever been to Utah, you might know that it is a highly religious state. The Mormon temples are proudly displayed and most stores are closed on Sunday. So it comes as no surprise that Senator Hatch is a dedicated Mormon.
But the Senator isn’t a blind follower. He sees the damage that opioid addiction causes and the good that cannabis can do. Especially as the U.S. grapples with spikes in teen overdose deaths rates. And the opioid crisis is causing a significant drop in U.S. labor force participation—particularly among American men. And Senator Hatch wants to stop it.
But the problem is bigger than just one state. The entire nation seems under the oppressive whip of opioid addiction. If you aren’t struggling with opioids, chances are you know someone who is. And most of them got hooked by their doctors.
Trump even declared the opioid crisis a national emergency and seeks solutions that will appease his base and his face. But Trump has yet to put forth a comprehensive sentence, much less a policy directing the nation on how to handle cannabis. And Hatch is much more pragmatic about his approach to dealing with this sensitive and rampant issue.

Senator Hatch has a plan for how to fight the opioid crisis.

As part of his plan to combat the opioid epidemic, Hatch introduced the Marijuana Effectiveness Drug Study Act of 2017 (MEDS Act). The speech he gave during the introduction Wednesday, he couldn’t help but sneak in some weed puns.
He started his speech by saying “Mr. President, it’s high time to address research into medical marijuana. Our country has experimented with a variety of state solutions without properly delving into the weeds on the effectiveness, safety, dosing, administration, and quality of medical marijuana.”
Hatch wore his religion on his sleeve but showed his willingness to compromise when he said “it will surprise no one that I am strongly against the use of recreational marijuana. I worry, however, that in our zeal to enforce the law, we too often blind ourselves to the medicinal benefits of natural substances like cannabis.”

He feels cannabis is a powerful ally in the fight.

Senator Hatch sees red tape as the big problem with cannabis today. He explained that there are no federal quality controls for marijuana-based medications. The MEDS Act would remedy that and establish standards for growing medicinal marijuana.
Bureaucratic red tape surrounding safety and efficacy prevent the kind of “rigorous scientific evidence” Hatch feels is still needed. He understands that there are many unique and powerful compounds in the cannabis plant. And the MEDS Act is his attempt at stimulating research into the potential of cannabis.
Like most of us, it took Senator Hatch a personal encounter to come around to cannabis. When a friend was faced with the choice between using weed and getting a risky brain operation, Hatch realized how important research into cannabis is.

Hatch isn’t a hippy.

He was quick to clarify that he wasn’t going to be advocating recreational consumption though. His very next words were “While I certainly do not support the use of marijuana for recreational purposes, the evidence shows that cannabis possesses medicinal properties that can truly change people’s lives for the better. And I believe, Mr. President, that we would be remiss if we threw out the baby with the bathwater.”
Senator Hatch wants to encourage research into potential medical uses for marijuana. The plan involves streamlining the research registration process. The goal is to make marijuana more available to the scientific and medical research communities.

The MEDS Act will make an impact if it passes.

Ideally, the bill will sail through both houses, get signed into law and become a new foundational piece of legislation moving forward. But that seems like a pipe dream. There is plenty of cannabis reform legislation making the rounds right now and none of it has much support.
More likely, it will suffer the same fate as the other pro-cannabis legislation making the rounds in congress. Bills like the Compassionate Care Act and the Research Expansion and Respect States (CARERS) Act couldn’t find the support they needed to move forward.
These bills are stuck in a state of limbo, dead on the floor and unable to pass on. Mainly because there isn’t enough support to pass them or even to get them to a vote. This effectively makes them zombie legislation with little hope of actually passing.

Senator Hatch wants to do things right.

The MEDS Act encourages commercial production of FDA-approved drugs derived from marijuana. It would also put pressure on the Attorney General (AG) to increase the national marijuana quota in a timely manner. It would do this by requiring the AG meet the nations changing medical, scientific and industrial needs for marijuana.
The bill would also include certain protections against abuse as well. The National Institute on Drug Abuse (NIDA) would then have to develop and publish recommendations and best practices. These would include how to grow and produce marijuana for research.
But there is still a long road ahead. Even if the bill gets passed, there will be many edits, re-writes and last minute additions. Political opponents will try to dismantle the important protections and stall it out like past bills. It’s hard to tell how far this one will go. But we can at least hope it goes all the way.

What do you think about Senator Hatch and the MEDS Act? Do you think it will become law? Let us know why or why not in the comments below.

Analysis/Opinion, Guides, Marijuana Legalization, Marijuana NewsApril 4, 2017 by Adam Rhodes

Investing in the Cannabis Industry 2017

Marijuana stock investing in 2016 has seen a meteoric rise.

Investing in cannabis is making some major money with one especially impressive company posting gains of well over 2,000%. This despite how fraught with risk this industry is. Since marijuana is still classified as a Schedule I substance with “no currently accepted medical use and a high potential for abuse,” according to the federal government, there are still some hurdles to overcome.
The National Commission on Marijuana and Drug Abuse issued a series of reports concluding that marijuana was “less a serious threat to public health than a sensitive social issue and recommended changes to federal law that would permit citizens to possess a small amount of it at a time, while still maintaining that the drug should not be legalized.” Yet investing remains risky because the people in power refuse to be moved to action.

Is $50 billion motivation enough?

Ackrell Capital projects that the cannabinoid-based pharmaceutical market could clear $50 billion annually. Investors took special not of the prediction due to the explosive growth the industry has seen so far. They make sure to include plenty of caveats in their report that basically boil down to legalization=money.
AbbVie (ABBV) is ahead of the game in medicinal marijuana field because its drug (Marinol) is already been approved by the Food and Drug Administration and in the market. Marinol is mainly used to relieve nausea and vomiting for chemotherapy patients. It has also been prescribed for AIDS patients to help stimulate appetite.
If you want to talk about AbbVie, let me just say that it has had 44 years of consecutive dividend increases. Over the past three years alone, the dividend has grown by 12.5%. the 4.13% dividend yield is considered attractive for income investors.
Just because they were first to the market doesn’t make them invincible though. Company revenues , gross profit and net income have been stagnant during the last four quarters. If Marinol can raise profits, AbbVie and others like it could be treated as an income play rather than a growth stocks for 2017.

There are currently 28 states willing to sell.

Support for use of medical marijuana is rapidly expanding along with investing opportunities. After the November U.S. elections, 28 states plus the District of Columbia now have legalized use of medical marijuana. A handful of states have also chosen to allow recreational use.
Legalization should diminish some of the institutional barriers for companies investing in the marijuana industry. Although we can see how slow the movement is by looking at recent court decisions about drug testing. The advancement of legalization on a state level presents a special opportunity for investors but at great risk.
Weed’s mis-classification as a schedule-I compound creates restrictions for patients in non-weed-friendly states. Not to mention how much of a damper it puts on investors’ plans. The chief regulator of Wall Street (Financial Industry Regulatory Authority or FINRA) blocked a S-1 filing from weed companies attempting to go public and trade stock. The ban will remain in place until the drug is re-scheduled.

There are only 3 approved options on the market.

While opportunities exist, current realities paint a stark picture. The U.S. Food and Drug Administration has approved a whopping total of three cannabinoid drugs. It took seemingly forever for another cannabinoid to join Marinol and Cesamet in the medicine cabinet.
In July of 2016, the FDA gave the go ahead for Insys Therapeutics’ (NASDAQ:INSY) Syndros to join the party. Like Marinol, the active ingredient of Syndros is the synthetic cannabinoid dronabinol. And don’t think that only drug companies are trying to get in on the action.
Investors sent shares of Scotts Miracle-Gro Co. up 48 percent last year when they saw the lawn-care company as a relatively safe way to capitalize on the cannabis trend. It sells fertilizers, lighting and other supplies for hydroponics that are used by most indoor cultivators.

One person can tip the scales.

A very important fact for investors considering investing in marijuana to remember is who the next attorney general is. And the person who got the nomination to fill that role was Alabama Republican Sen. Jeff Sessions. A man who is an adamant opponent of legalized marijuana.
In a Senate hearing last April, Sessions cited a 20% increase in the traffic deaths in some states where marijuana has been legalized to show the drug is a problem. His continued vigorous attempts to demonize cannabis users signals major disappointment for those hoping for banking reform.
Marijuana companies have continued to struggle with limited access to basic banking services since most banks fear federal prosecution for dealing with pot businesses. Being forced to operate on a cash-only basis is a security concern and an expansion inhibitor for any business. With Sessions taking the helm, there is little hope for meaningful pressure to improve access to banking services. Additionally, marijuana businesses must pay tax on their gross profits instead of net profits. This is because they’re disallowed normal corporate income tax deductions.

How should you approach the industry?

It has been said that getting rich during a gold rush is to easiest when you sell shovels. With that in mind, the best figure for investors trying to turn a profit from the “marijuana rush” are the companies that have zero marijuana-related products. The smartest play might be in companies that have the potential to benefit by serving people and companies that do sell cannabis.
But before you invest in any company, get as much information about that company as you possibly can. Find out if they are a legitimate company with a good management team. Look into who’s running the company and at the company’s finances. Don’t be afraid to go over the balance sheet, the cash flow, the income statement, and the shareholder’s equity.
Look at all of the info you can before making a decision. Call the nearby Chambers of Commerce, find out if they know the people or company. Don’t forget to look at the other officers and management to make sure the engine is firing on all cylinders if you catch my drift. Do all the research you can but don’t forget to talk to your financial advisor as well before pulling the trigger.
The early bird doesn’t always get the worm.

Companies are making serious efforts to develop effective medicines using on cannabis. These companies deserve all due diligence before investing in any of them. Understand that investing in potential is risky and any of the drugs discussed in this article could fail or disappoint. Some medicinal marijuana stocks will undoubtedly succeed in 2017, so research and be vigilant when navigating this exploding industry. But don’t forget all the good that cannabis can do.
Cannabinoids have been found to have potential in treating over 40 medical issues including cancer, chronic pain, epilepsy, and glaucoma. Companies developing marijuana-related compounds rarely focus on cannabis alone. Be aware that some “mainstream” stocks may actually profit from loosened restrictions on marijuana even if they don’t grow or sell it themselves. Thanks for reading.

Analysis/Opinion, Culture, Marijuana Legalization, Marijuana News, Medical, ScienceFebruary 24, 2017 by Adam Rhodes

DEA: Marijuana is Not a Gateway Drug

Marijuana has been called a gateway drug for over 80 years.

The battle lines were drawn long before anyone currently driving the gateway debate had assumed power. Political figures have demonized cannabis and those who consume it for almost a century and worked to create a massive industrial prison complex designed to harvest people. Low income and minority people have borne the brunt of the assault.
Americans have been tricked into accepting the most ridiculous claims about cannabis and a whole generation of people have grown up behind bars because of it. Politicians have used slippery speech to sway public opinion and outright changed the law in order to suite their desires for decades. When Reagan and Clinton enacted laws that put more people in jail than the Romans had slaves.
Larry Anslinger didn’t care about how many would suffer without the healing properties of cannabis, he was motivated by an zealous hatred for the plant to create the movie Reefer Madness. President Nixon was motivated by a religious desire to punish people regardless of what his own investigators proved. Reagan had no mercy for people caught in the crossfire when he enacted draconian mandatory punishments for minor drug infractions.

We stand at the dawn of a new era of American drug policy.

Despite an abundance of empirical evidence about the medical benefit of cannabis from reputable medical professionals from the Shafer Commission to Sanjay Gupta, it remains a schedule 1 controlled substance. This classifies weed as having “no medical benefits” and creates massive hurdles for scientists and doctors looking to research cannabis. It also puts it in the same medical category as heroin.
With the rise of Trump and the appointment of Jeff Sessions to Attorney General, the entire industry is bracing for another impact. Part of the collective wince comes from the evasive actions of top officials on the matter through election season. Instead of giving clear messages about how they plan to pursue policy, government officials are as vague as possible about how they plan to pursue policy.
This evasive attitude has made many wary of the how the Trump Administration plans to deal with cannabis. Statements in the past by Jeff Sessions like “Good people don’t smoke marijuana.” and his past issues of discriminatory prosecution during the Civil Rights movement has helped to stir up old debates.

The debate surrounding legalizing marijuana has resurrected the Gateway Theory.

This theory presumes that experimenting with marijuana inevitably results in the use of harder drugs like cocaine, heroin and methamphetamine. Until recently, the DEA website contained dozens of lies and inaccuracies and it begrudgingly changed them only after being threatened with legal action.
Many people don’t know that it is illegal for federal agencies to spread incorrect information. Yet when it comes to cannabis, the Drug Enforcement Administration (DEA) has been doing it for years. In less than a month, a petition from Change.org calling on the DEA by a to stop lying about medical cannabis received 85,000+ signatures.
The petition was started by Americans for Safe Access (ASA), a nonprofit organization working to increase access to medical cannabis. “The DEA has actually admitted that the theories that cannabis use leads to harder drugs (gateway theory), long-term brain damage, psychosis, and other alleged harms, are not based in scientific fact, and yet they keep distributing this false information”, says ASA. “[W]e have found 25 instances of these false claims on their website.”

The petition for updated information was direct and their arguments were air-tight.

The group argued that the document previously known as “The Dangers and Consequences of Marijuana Abuse,” had a few inaccurate claims about cannabis. They showed how the page was in violation of the Information Quality Act which requires that administrative agencies provide accurate information to the public. The DEA also had to respond to requests for correction of information within 60 days.
A separate petition was filed by the Department of Justice demanding that the DEA immediately update misinformation about cannabis. While neither the DEA nor the DOJ responded to ASA’s request, the document which contained the majority of the inaccurate statements was removed from their website.
But the governement is made up of more people than ever before. There is a lot of room for competing ideologies and goals to play out. A key observation of the Shafer Commission is that many of the risks of drug use are the result of drug policy/enforcement rather than from the drugs themselves.

The “gateway drug” stigma refuses to die.

A prime example of how this stigma presents itself is New York governor Andrew Cuomo. He wants to keep cannabis illegal in New York State because it “leads to other drugs and there’s a lot of truth to proof that that’s true.” He holds this view despite the results of a major study on medical marijuana conducted by the venerable Institute of Medicine, which included an examination of marijuana’s potential to lead to abusing other drugs.
The study found that “There is no conclusive evidence that the drug effects of marijuana are causally linked to the subsequent abuse of other illicit drugs.” Even the DEA has gone on record to say “Little evidence supports the hypothesis that initiation of marijuana use leads to an abuse disorder with other illicit substances,” while refusing to reschedule cannabis in August of 2016.
The continuing stigma prevents meaningful reform of marijuana laws by perpetuating harmful misinformation. A Rasmussen poll found that a large percentage of Americans believe the gateway argument. Nearly half of voters (46%) believed marijuana use leads to harder drugs. Thirty-seven percent (37%) did not see marijuana as a “gateway” drug.

Patterns in progression of drug use are strikingly regular.

Because it is the most widely used illicit drug, marijuana is predictably the first illicit drug most people come across. Not surprisingly, most users of other illicit drugs used marijuana before the harder stuff. In fact, most adult users begin with alcohol and nicotine long before moving on to cannabis and other illicit drugs.
In 2006, the University of Pittsburgh released a thorough study which researchers spent 12 years putting together. They tracked a group of subjects from adolescence into adulthood and documented the initiation and progression of their drug use. The researchers reported that the gateway theory was not only wrong, but also detrimental to properly understanding and addressing drug abuse.
The myth of the Gateway effect needs to be put to rest once and for all. The more research that is conducted the clearer it becomes that cannabis use does not lead to abuse of other drugs. Some promising research has also shown that cannabis can actually help people kick the other stuff like heroine. As more and more states legalize medical and recreational marijuana, it is more important than ever to put the gateway myth to rest. Thanks for reading.

drug